Furthermore, the TGF-β receptor inhibitor LY2157299 encapsulated in NPs and siPD-L1 accumulated on the NP surface, enhanced anti-tumor activity in the subcutaneous Panc02 xenograft mice model by silencing PD-L1 gene expression in tumor cells and promoting CD8+ T cell proliferation, resulting in suppression of tumor growth (Wang et al., 2020b). Here, CD8A is linked to neoplasm.